Emergent BioSolutions, Inc.
(EBS:NYSE)
Snapshot of Emergent BioSolutions, Inc. (EBS)
|
OPEN
$13.91
|
PREVIOUS CLOSE
$13.79
|
|
|
DAY HIGH
$14.09
|
DAY LOW
$13.88
|
|
|
52 WEEK HIGH
01/2/09 - $27.00
|
52 WEEK LOW
05/6/09 - $9.15
|
|
|
MARKET CAP
430.6M
|
AVERAGE VOLUME 3 mo
512.2K
|
|
|
DILUTED EPS TTM
$0.91
|
SHARES OUTSTANDING
30.8M
|
|
|
EBS Does Not Pay Dividends
|
P/E TTM
15.4x
|
|
| K = Thousands M = Millions B = Billions | ||
EBS Details
Emergent BioSolutions Inc. develops, manufactures, and commercializes immunobiotics such as vaccines and immune globulins that assist the body’s immune system. The company’s biodefense segment develops, manufactures, and commercializes drugs such as BioThrax, a vaccine for the prevention of anthrax, for use against biological agents. Other products in preclinical development include drugs for the treatment of patients after they are exposed to anthrax and botulinum toxin. Emergent’s commercial segment develops products for use against infectious diseases. These include a single-dose typhoid vaccine in phase II clinical development; a hepatitis B vaccine in phase II clinical development, and a group B streptococcus vaccine for women of childbearing age for protection of the fetus and newborn babies, which is in phase I clinical trials. Emergent is also developing chlamydia and meningitis B vaccines. Emergent primarily works for the U.S. Defense and Health & Human Services departments. It has collaboration agreements with the British Health Protection Agency for the development of a human botulinum immune globulin candidate and with Sanofi Pasteur for the development of meningitis B vaccine candidate. The company, which was founded in 1998, is based in Rockville, Maryland.
EBS Top Compensated Officers
Key developments for Emergent BioSolutions, Inc. (EBS)
Emergent BioSolutions Inc. announced unaudited consolidated financial results for the third quarter and nine months ended September 30, 2009. For the quarter, the company's total revenues were $43.3 million against $56.6 million a year ago. Net income was $0.9 million, or $0.03 per basic share. Loss from operations was $3.95 million against $15.3 million a year ago. Loss before provision for income taxes was $3.5 million against income before income tax of $15.8 million a year ago. Net income attributable to company was $949,000 or $0.03 diluted per share against $10.4 million or $0.34 diluted per share a year ago. For the nine months, the company's total revenues were $180.9 million against $142.8 million a year ago. Net income was $26.9 million or $0.89 per basic share. Income from operations was $36.02 million against $29.1 million a year ago. Income before provision for income taxes was $37.01 million against $30.8 million a year ago. Net income attributable to company was $26.9 million or $0.86 diluted per share against $19.2 million or $0.64 diluted per share a year ago. Net cash provided by operating activities was $53.8 million against $19.3 million a year ago. Purchases of property, plant and equipment was $14.4 million against $16.5 million a year ago. The company reaffirmed earnings guidance for the year 2009. For the year, the company is forecasting 25% to 35% growth in year-over-year total revenue to approximately $225 to $240 million. The Company also anticipates 2009 net income in excess of $20 million.
R. Don Elsey, Chief Financial Officer of Emergent BioSolutions, Inc., said, “In addition, we continue to invest in our manufacturing and product development infrastructure through the purchase of two separate facilities that provide additional flexibility and reduced annual operating expenses. Finally, we continue to pursue expansion of our product portfolio through acquisition and in-licensing.”
To provide a corporate overview, including a discussion of product development programs, corporate activities and financial performance
BusinessWeek Rankings
Stock Quotes
| Recently Viewed | |||
| EBS | $13.98 USD | +0.19 |  |
|---|---|---|---|
| MIDD | $46.36 USD | +0.17 |  |
| ALTR | $20.83 USD | +0.16 |  |
| ARLP | $38.85 USD | -0.10 |  |
| BOOM | $20.21 USD | +0.30 |  |
Market data is delayed at least 20 minutes.
EBS Competitors
| Company | Last | Change |
| Bavarian Nordic | kr170.00 DKK | -1.50 |
| Cangene Corp | C$5.85 CAD | +0.11 |
| Human Genome Sciences Inc | $27.38 USD | 0.00 |
| PharmAthene Inc | $3.49 USD | +0.01 |
| Salix Pharmaceuticals Ltd | $23.46 USD | +0.05 |
| View Industry Companies | ||
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | EBS | Industry Range |
| Price/Earnings | 15.2x |
|
| Price/Sales | 1.9x |
|
| Price/Book | 1.8x |
|
| Price/Cash Flow | 15.0x |
|
| TEV/Sales | 1.2x |
|
|
EBS |
||
EBS transactions
| Type Date |
Target |
|
Merger/Acquisition
July 31, 2009 |
Emergent BioSolutions, Inc., Two Facilities in Frederick |
Companies Toolbox
Update/report
Submit private company
Upload your company video
Newsletter
Blogs
RSS feeds
Podcasts
VideosSEARCH FOR JOBS
Post a Job- Painesville, OH-Avery Dennison
- Houston, TX-Halliburton
- Houston, TX-Halliburton
- New York, NY-Duff & Phelps
Jobs by SimplyHired
Recommend A Data Enhancement Or Correction
For Emergent BioSolutions, Inc. (EBS) Snapshot
Submitting this data update / error report instantly puts the correct information in the hands of our researcher, who will investigate your report and, if necessary, make the changes to the company profile. Be sure to fill out the form completely.
Please indicate in which section the error appears. Section headers are in light gray type at the top of each CIC page module.
Please indicate which data is in error.
Please provide your name and email address in case our researchers need to get in touch with you as they investigate the error.
Describe why you feel the data point is incorrect and indicate sources our researchers should check when they investigate the error.
